Natera agreed to acquire Foresight Diagnostics for $275 million upfront plus up to $175 million in earnouts to integrate PhasED‑Seq phased‑variant technology into Natera’s Signatera MRD platform. The deal combines Foresight’s high‑sensitivity ctDNA assays—reported limits of detection below 0.1 parts per million—with Natera’s commercial reach to accelerate MRD adoption in lymphoma and other solid tumors. Natera said the enhanced Signatera will be available for research use immediately and expects a clinical launch in 2026. Analysts note the acquisition strengthens Natera’s sensitivity claims and opens access to lymphoma indications where phased‑variant approaches have traction.